Immunomedics, Inc. (IMMU) News

Immunomedics, Inc. (IMMU)

Today's Latest Price: $87.86 USD

0.04 (0.05%)

Updated Oct 22 12:00am

Add IMMU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter IMMU News Items

IMMU News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest IMMU News From Around the Web

Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.

Gilead Makes A Sizeable Bet On Immunomedics

Trodelvy. Source: Fierce Pharma Gilead (GILD) just unpacked part of its $21 billion war chest to acquire Immunomedics (IMMU) for $21 billion. "The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate ((ADC)) that was granted accelerated approval by the U.S. Food and Drug Administration...

Shock Exchange on Seeking Alpha | September 26, 2020

Immunomedics' trodelvy shows 27% response rate in urothelial cancer

Immunomedics (IMMU) announced positive results from cohort 1 (n=113) of cisplatin-eligible patients in Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC).Results confirmed the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC...

Seeking Alpha | September 21, 2020

Immunomedics Trodelvy extends survival benefit in late-stage triple-negative breast cancer study

Immunomedics (IMMU) announces results from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) compared to treatment of choice ((TPC)) standard single-agent chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least two prior therapies for metastatic disease. These results were presented at the ESMO Virtual...

Seeking Alpha | September 21, 2020

The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix

Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual ...

Benzinga | September 20, 2020

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)

GlobeNewswire | September 18, 2020

Wachtell regains top M&A perch, leapfrogging Latham for now

With the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser based on transaction value for 2020, after advising biotech company Immunomedics Inc on its agreement to be acquired by Gilead…

Reuters | September 17, 2020

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

What will it take for Gilead to break even on its $21 billion deal?

The deal, which gives Gilead control of Immunomedics, came at a more than 100% premium to the latter firm's most recent stock price.

STAT News | September 15, 2020

Immunomedics, Cassava Sciences leads gainers pack, Nano-X Imaging, Teligent among major losers

Gainers: Immunomedics (IMMU) +101%, Cassava Sciences, (SAVA) +78%, Vaxart (VXRT) +28%, Mersana Therapeutics (MRSN) +17%, Venus Concept (VERO) +15%.Losers: Nano-X Imaging (NNOX) -14%, Teligent (TLGT) -12%, Mallinckrodt (MNK) -12%, Kala Pharmaceuticals (KALA) -12%, Co-Diagnostics (CODX) -11%....

Seeking Alpha | September 14, 2020

VXRT, IMMU, GRPN and CODX among midday movers

Gainers: Immunomedics (IMMU) +100%.Cassava Sciences (SAVA) +86%.Vaxart (VXRT) +48%.Scientific Games (SGMS) +44%.Mersana Therapeutics (MRSN) +25%.Evogene (EVGN) +24%.Select Energy Services (WTTR) +23%.NextDecade (NEXT) +20%.Trevena (TRVN) +20%.DiamondPeak (DPHC) +20%.Losers: Nano-X Imaging (NNOX) -15%.Teligent (TLGT) -13%.Co-Diagnostics (CODX) -13%.Groupon (GRPN) -12%.9F (JFU) -12%.OneWater Marine (ONEW) -12%.Kala Pharmaceuticals (KALA) -11%.Goosehead Insurance (GSHD) -11%.Salem Media (SALM) -9%.Astrotech (ASTC) -9%....

Seeking Alpha | September 14, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4979 seconds.